Collectively, these results suggest that tumor cell biology underlying TGF-β signaling in an untreated prostate cancer setting is significantly associated with greater propensity to progress, manifesting clinically as a biochemical recurrence after RT. The gene discussed is TGFB1; the disease is prostate carcinoma.